Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Sonnet BioTherapeutics Holdings ( (SONN) ) has provided an update.
Sonnet BioTherapeutics has achieved a significant milestone in its Phase 1 SB101 trial for SON-1010, a targeted immunotherapeutic drug, by establishing a maximum tolerated dose of 1200 ng/kg without dose-limiting toxicity. The trial results indicate a promising 48% stability in disease among patients, with one experiencing a notable 45% tumor reduction. These findings highlight the potential of SON-1010 in treating advanced solid tumors, sparking interest for further development and partnerships.
For a thorough assessment of SONN stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Shareholder Alert for Dentsply Sirona, Inc. (NASDAQ:XRAY)
- Shareholder Alert for Warner Bros. Discovery, Inc. (NASDAQ:WBD)
- 3 Penny Stocks to Watch Now, 12/10/24
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
